Biotech
Commented by Armin Schulz on November 19th, 2021 | 11:21 CET
Valneva, Cardiol Therapeutics, Novavax - Is the Corona emergency brake coming?
Today, the Robert Koch Institute reported 65,371 new infections, a new sad record. In Berlin, politicians are currently discussing how to proceed. Abolishing the free tests to increase the pressure on the unvaccinated has proven wrong in retrospect. The fact that booster vaccinations might be necessary was also not considered when the vaccination centers were closed. Now the first state is discussing the next lockdown. If the numbers continue to rise, the emergency brake will be pulled in Berlin sooner or later. In parts of Austria, it is already a reality. We take a look at three possible winners of a lockdown.
Read
Commented by Stefan Feulner on November 15th, 2021 | 10:50 CET
Valneva, XPhyto, NanoRepro - Here we go again
Although around 67.4% of the population in Germany is already fully vaccinated, the infection figures are rising to unprecedented heights. The fourth wave with the highly contagious Delta variant is rolling across the republic. This development must be stopped as quickly as possible. In addition to booster vaccinations, politicians are therefore reintroducing citizen testing as a tool against the spread. For diagnostics companies and providers of rapid tests, this means a boom and further increases in earnings, likely to be reflected in stock market valuations in the near future.
Read
Commented by André Will-Laudien on November 8th, 2021 | 12:08 CET
BioNTech, Moderna, Cardiol Therapeutics, Valneva: COVID-19, the vaccination chaos is perfect!
Now the chaos is perfect. According to studies, the preparation from BioNTech/Pfizer is one of the most effective vaccines against the coronavirus. Hundreds of millions of doses have already been administered worldwide. However, the number of COVID infections is currently through the roof. Even those who have been vaccinated twice are likely still not sufficiently protected against infection. There are also unsettling rumors from BioNTech about irregularities in the conduct of studies during the vaccine's approval. Whether it concerns thereby only "rumors" or "provable facts", the capital investors do not care for the time being. They pressed the sell button and thus sent the entire peer group Adhoc into the basement. We take a closer look at the chaos.
Read
Commented by Stefan Feulner on November 5th, 2021 | 11:22 CET
BioNTech, Sativa Wellness, Merck KGaA - Impressive trend
There is no question that vaccine manufacturers are one of the main winners of the Corona pandemic. The recently presented quarterly figures of Pfizer, BioNTech's partner, show this impressively and suggest that the Mainz-based Company will also announce a sales explosion on November 9. Booster vaccinations are likely to continue this trend. Currently, encouraged by legalization, the cannabis industry is also experiencing a new upswing. Be a part of it from the beginning.
Read
Commented by André Will-Laudien on November 3rd, 2021 | 13:26 CET
CureVac, Ayurcann, Novavax, NanoRepro: Things are going through the roof here!
Healing and well-being are the focus of many biotech and pharmaceutical companies. In many cases, long research is carried out in order to get corresponding active substances on the way. After many clinical test series, the laborious approval process with the corresponding health authorities then begins. Some companies have provided themselves with good growth capital thanks to the high liquidity on the stock markets and are at the cutting edge with their products. We take a closer look at the industry.
Read
Commented by Armin Schulz on November 3rd, 2021 | 11:03 CET
MorphoSys, Defence Therapeutics, Formycon - Biotech and pharma offer potential for the portfolio
The pharmaceutical industry alone has annual sales of over EUR 1,000 billion worldwide and helps people overcome their illnesses. Since the Corona pandemic, biotech and pharma companies are even more in the spotlight. If a company manages to develop a blockbuster, big profits also beckon to shareholders. BioNTech is currently a prime example of this, even if the share has consolidated in the meantime. Where there are high profits, there is also a higher risk. The road to the development and approval of a drug is long, and failure is also possible. As people are getting older and diseases are rising, it makes sense to invest in these areas. Today we analyze three potential candidates.
Read
Commented by Stefan Feulner on November 3rd, 2021 | 10:16 CET
Valneva, Cardiol Therapeutics, BioNTech - Is the vaccination subscription coming?
The numbers of people infected with Corona have been rising significantly again for weeks. While only about 67% of Germans are fully vaccinated, the pace is slowing noticeably. Meanwhile, the third dose, the so-called "booster" vaccination, has already been started. The Standing Commission on Vaccination (STIKO) has recommended this booster for people aged 70 and over. A decision on whether booster vaccinations should be offered to everyone is likely to be made soon. For vaccine manufacturers, this means recurring revenues.
Read
Commented by Stefan Feulner on October 21st, 2021 | 12:17 CEST
Sartorius, Defence Therapeutics, QIAGEN - Still long potential
Since the outbreak of the Corona pandemic, biotech and pharmaceutical shares have been among the top performers on the stock market. In addition to vaccine producers such as BioNTech and Pfizer, the share price of the US pharmaceutical Company Moderna also multiplied. Other winners included diagnostics companies and laboratory equipment suppliers, process technology specialists and manufacturers of biopharmaceuticals. Biopharmaceuticals promise enormous growth potential even after Corona, especially the market such as gene and cell therapies is growing dynamically at the moment.
Read
Commented by Armin Schulz on October 20th, 2021 | 11:04 CEST
Bayer, Sativa Wellness Group, MorphoSys - Can the pharmaceutical industry benefit from the new German government?
The federal election is over, and the pharmaceutical industry has to adjust to the new political constellation. The industry is facing change. Digitization is an important topic. To not lose even more researchers to foreign countries, approval processes must be accelerated and bureaucracy reduced. If we always acted as decisively as we did during the pandemic, much more could be achieved. The new federal government is flirting with the legalization of cannabis. If this were to happen, the market would probably be huge. The next four years promise to be exciting.
Read
Commented by Nico Popp on October 18th, 2021 | 10:44 CEST
BioNTech, Cardiol Therapeutics, Bayer: Where triple-digit returns beckon
The pandemic is drawing to a close. Vaccination rates are high, and a new wave is - fortunately - not picking up speed. But in this environment, what is happening to many highly acclaimed pandemic stocks? Are vaccine manufacturers still interesting at the moment? We look at how the industry is faring and where opportunities can still be found.
Read